Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Prevention and risk

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Poorer cognitive function and an increased risk of vascular dementia (VaD) were found to be associated with a lower consumption of milk or dairy products. However, the consumption of whole-fat dairy products may be associated with cognitive decline in the elderly. Light-to-moderate alcohol use may be associated with a reduced risk of incident dementia and AD, while for VaD, cognitive decline and predementia syndromes, the current evidence is only suggestive of a protective effect. Only recently, higher adherence to a Mediterranean-type diet was associated with decreased cognitive decline, although the Mediterranean diet (MeDi) combines several foods, micro- and macro-nutrients already separately proposed as potential protective factors against dementia and predementia syndromes. In fact, recent prospective studies provided evidence that higher adherence to a Mediterranean-type diet could be associated with slower cognitive decline, reduced risk of progression from MCI to AD, reduced risk of AD and a decreased all-cause mortality in AD patients. These findings suggested that adherence to the MeDi may affect not only the risk of AD, but also of predementia syndromes and their progression to overt dementia.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Solfrizzi, V., Panza, F., Frisardi, V., Seripa, D., Logroscino, G., Imbimbo, B. P., et al. (2011). Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert review of neurotherapeutics. https://doi.org/10.1586/ern.11.56

Vancouver

Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, et al. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert review of neurotherapeutics. 2011. doi:10.1586/ern.11.56. PMID: 21539488.

BibTeX

@article{solfrizzi2011-21539488,
  author  = {Solfrizzi, V. and Panza, F. and Frisardi, V. and Seripa, D. and Logroscino, G. and Imbimbo, B. P. and Pilotto, A.},
  title   = {{Diet and Alzheimer's disease risk factors or prevention: the current evidence}},
  journal = {Expert review of neurotherapeutics},
  year    = {2011},
  doi     = {10.1586/ern.11.56},
  pmid    = {21539488},
  url     = {https://doi.org/10.1586/ern.11.56}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This review reports that higher adherence to a Mediterranean-type diet was linked to slower cognitive decline and reduced risk of Alzheimer's disease in prospective studies. These are observational findings and do not prove that diet prevents or treats Alzheimer's disease.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Expert review of neurotherapeutics)
Journal's citation record 1 / 4 Expert Review of Neurotherapeutics: journal h-index 125 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2011 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 299 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 17.6 citations a year over 17 year(s) since 2011
Impact for its field and year 4 / 6 Cited 13.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 5 other studies in this library
Still being cited 2 / 4 Cited 43 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Alberto Pilotto: h-index 45 (OpenAlex, whole career)
Institution's track record 0 / 3 University of Bari Aldo Moro: institution h-index 586 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21539488)
Free to read 0 / 2 Behind a paywall — scores zero
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 56.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Prevention and risk from nearby years

Also in Prevention and risk

265 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →